Loading...
Bilateral Trade Intelligence · $13.3K Total Trade · 3 Foreign Suppliers · 5 Indian Buyers · DGFT Verified · Updated March 2026
India imported $13.3K worth of pharmaceutical formulations from Cyprus across 46 verified shipments, from 3 foreign suppliers to 5 Indian buyers. The top suppliers are REMEDICA LTD ($7.3K) and REMEDICA LIMITED ($5.2K). The leading products are Lapatinib ($5K) and Erlotinib ($4K). Average shipment value: $290.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Lapatinib | $5.2K | 38.7% |
| 2 | Erlotinib | $4.4K | 33.0% |
| 3 | Ritonavir | $1.8K | 13.8% |
| 4 | Darunavir | $743 | 5.6% |
| 5 | Nilotinib | $331 | 2.5% |
| 6 | Iron | $275 | 2.1% |
| 7 | Spironolactone | $275 | 2.1% |
| 8 | Cephalexin | $158 | 1.2% |
| 9 | Citalopram | $47 | 0.4% |
| 10 | Escitalopram | $47 | 0.4% |
| 11 | Ibuprofen | $15 | 0.1% |
| 12 | Azithromycin | $15 | 0.1% |
| 13 | Valsartan | $13 | 0.1% |
| 14 | Sodium | $2 | 0.0% |
| 15 | Magnesium | $1 | 0.0% |
India imports 16+ pharmaceutical formulations from Cyprus with a combined trade value of $13.3K. Key products include Lapatinib ($5K), Erlotinib ($4K), Ritonavir ($2K), Darunavir ($743), Nilotinib ($331). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 46 verified Indian Customs (DGFT) shipment records.
3 Indian pharmaceutical companies export finished formulations to Cyprus. Leading exporters include Remedica Ltd, Remedica Limited, Remedica Ltd., . The top exporter accounts for 55.1% of total India–Cyprus pharma exports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Cyprus and India has experienced modest activity from 2022 to 2026. Over this period, India imported pharmaceutical formulations from Cyprus totaling $13,000 USD across 46 shipments. The average shipment value was approximately $290 USD, indicating a niche yet consistent trade relationship. Cyprus's pharmaceutical exports to India are primarily composed of finished formulations, including tablets, capsules, syrups, and injections. This trend underscores Cyprus's role as a supplier of ready-to-use pharmaceutical products to the Indian market.
Cyprus's contribution to India's pharmaceutical imports remains relatively small. In 2024, Cyprus exported pharmaceutical products worth $687,620 USD to India, accounting for a fraction of India's total pharmaceutical imports. The primary categories imported from Cyprus include medicaments put up in packings for retail sale, reflecting Cyprus's focus on finished pharmaceutical products. This aligns with the data from 2022 to 2026, where Cyprus's pharmaceutical exports to India were valued at $13,000 USD across 46 shipments, with an average shipment value of $290 USD.
These are the top pharmaceutical products exported from India to Cyprus, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Cyprus buyers, regulatory requirements, and logistics for that specific product corridor. Products include Lapatinib ($5K), Erlotinib ($4K), Ritonavir ($2K), Darunavir ($743), Nilotinib ($331) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
5 companies in Cyprus import pharmaceutical formulations from India. Top buyers include Qps Bioserve India Private Limited, Veeda Clinical Research Limited, Synapse Labs Private Limited, Perfomics Analytical Labs Llp. The largest buyer accounts for 72.4% of India–Cyprus pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, there have been notable developments in India's pharmaceutical import policies. In February 2026, the Drugs Controller General of India (DCGI) announced the removal of the Export No Objection Certificate (NOC) requirement for pharmaceutical products destined for countries with Stringent Regulatory Authorities (SRAs), including the European Union. This policy change aims to streamline export procedures and enhance trade efficiency. However, as of March 2026, there is no specific information indicating that this policy change has directly impacted the import of pharmaceutical products from Cyprus to India.
Registration process, GMP requirements, import documentation
Cypriot pharmaceutical companies seeking to export products to India must navigate the registration process with the Central Drugs Standard Control Organisation (CDSCO). This process involves obtaining an import license (Form 10) and registering each product with the CDSCO. The registration requires comprehensive documentation, including a Certificate of Analysis (CoA) from an accredited laboratory, verifying the product's quality, purity, and potency. Additionally, a Certificate of Pharmaceutical Product (COPP) from the CDSCO is necessary for each pharmaceutical item, certifying compliance with Indian regulatory standards. The timeline for obtaining these approvals can vary, but it typically involves a thorough review process to ensure compliance with India's stringent pharmaceutical regulations.
India mandates that all pharmaceutical products imported into the country adhere to Good Manufacturing Practice (GMP) standards. Cypriot manufacturing sites must comply with these standards, which are in line with the World Health Organization (WHO) prequalification requirements. The CDSCO conducts inspections to verify compliance with GMP guidelines. These inspections assess various aspects, including manufacturing processes, quality control measures, and storage conditions, to ensure that imported pharmaceutical products meet India's quality and safety standards.
Importing pharmaceutical products into India from Cyprus requires several key documents:
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical products imported from Cyprus to India are predominantly used in the treatment of various cancers and HIV/AIDS. The top five products imported include:
1. Lapatinib: $5,000 USD (38.7%)
2. Erlotinib: $4,000 USD (33.0%)
3. Ritonavir: $2,000 USD (13.8%)
4. Darunavir: $743 USD (5.6%)
5. Nilotinib: $331 USD (2.5%)
These products are essential in oncology and antiretroviral therapy, indicating a focused demand in these therapeutic areas.
Cyprus exports several innovator drugs and novel formulations to India, particularly in the oncology and HIV/AIDS treatment sectors. These include:
These products are not manufactured domestically in India, highlighting the need for imports to meet treatment requirements.
India's importation of pharmaceutical products from Cyprus is driven by several factors:
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
These tariffs and taxes are subject to change based on government policies and trade agreements.
As of March 2026, there is no specific Free Trade Agreement (FTA) between India and Cyprus. However, both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations. Additionally, India's participation in the Regional Comprehensive Economic Partnership (RCEP) and other bilateral negotiations may influence trade dynamics, including pharmaceutical imports from Cyprus.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations are patented. This can impact the importation of certain pharmaceutical products. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported ones, to make them affordable for the public. Compulsory licensing provisions allow the government to grant licenses to produce patented products without the consent of the patent holder under specific circumstances, such as public health emergencies.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Cyprus to India typically utilize major sea routes, with transit times varying based on the shipping method and specific ports involved. Air freight is also an option, offering faster delivery times but at higher costs. The reliability of these routes is generally high, with established shipping lines and logistics providers facilitating the movement of goods.
Cyprus's main export ports include Limassol and Larnaca, which handle a significant portion of the country's pharmaceutical exports. In India, major import ports such as Mumbai, Chennai, and Kolkata are equipped to handle pharmaceutical shipments, ensuring compliance with regulatory requirements and maintaining product integrity during transit.
Upon arrival in India, pharmaceutical imports undergo customs clearance, which includes documentation verification and, if necessary, quality testing by the CDSCO. Maintaining the cold chain is crucial for certain pharmaceutical products, and Indian customs procedures ensure that temperature-sensitive goods are stored and transported under appropriate conditions. Compliance with Good Distribution Practice (GDP
India exported pharmaceuticals worth $13.3K to Cyprus across 46 verified shipments.
1. REMEDICA LTD — $7.3K. 2. REMEDICA LIMITED — $5.2K. 3. REMEDICA LTD. — $823. Total: 3 suppliers.
1. QPS BIOSERVE INDIA PRIVATE LIMITED — $9.6K. 2. VEEDA CLINICAL RESEARCH LIMITED — $2.6K. 3. SYNAPSE LABS PRIVATE LIMITED — $1.0K. 5 buyers total.
1. Lapatinib ($5.2K, 38.7%); 2. Erlotinib ($4.4K, 33.0%); 3. Ritonavir ($1.8K, 13.8%); 4. Darunavir ($743, 5.6%); 5. Nilotinib ($331, 2.5%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $13.3K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$290 per consignment across 46 shipments.
3 Indian companies. Largest: REMEDICA LTD with $7.3K.
TransData Nexus covers 3 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 46 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Exporters
5 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists